Nifedipine Morningside

Nifedipine, the active ingredient in Nifedipine Morningside, is a calcium channel blocker presented as an oral tablet (strength unspecified) for oral use. It treats hypertension, angina pectoris and Raynaud's phenomenon in adult patients.

GNH USA supplies Nifedipine Morningside as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nifedipine acts on vascular smooth muscle to lower blood pressure and improve coronary blood flow, making it useful in several cardiovascular conditions.

- Hypertension: reduces peripheral vascular resistance, helping to lower systolic and diastolic blood pressure. - Angina pectoris: alleviates chest pain by enhancing myocardial oxygen supply through vasodilation. - Raynaud's phenomenon: diminishes frequency and severity of vasospastic attacks in extremities.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness - Tachycardia - Nausea

Serious or Rare Side Effects: - Severe hypotension - Myocardial infarction - Life‑threatening arrhythmias - Elevated liver enzymes - Allergic reactions (e.g., rash, angioedema) - Blood cell disorders such as leukopenia or thrombocytopenia

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Monitor blood pressure: ensure adequate control without excessive hypotension. - Assess cardiac function: especially in patients with existing heart disease. - Use caution in hepatic impairment: dose adjustments may be required. - Avoid abrupt discontinuation: taper to prevent rebound hypertension. - Review concomitant medications: consider additive effects on blood pressure. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nifedipine may interact with several drug classes, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - Grapefruit juice: can markedly raise nifedipine concentrations. - Concurrent use with other calcium channel blockers: risk of additive hypotension. - High‑dose diuretics: may cause electrolyte disturbances and excessive blood pressure drop. - Nitrates: combined effect can lead to severe hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance bradycardia. - ACE inhibitors or ARBs: monitor for additive blood pressure reduction. - NSAIDs: may blunt antihypertensive effect. - Digoxin: increased risk of arrhythmias. - Alcohol: can potentiate central nervous system effects such as dizziness.